Research ArticleOriginal Article
Open Access

Overexpression of SIRT1 in urothelial carcinoma of the urinary bladder is associated with local recurrence and poor survival

Jaudah A. Al-Maghrabi
Saudi Medical Journal June 2019, 40 (6) 541-547; DOI: https://doi.org/10.15537/smj.2019.6.24248

References

  1. ↵
    1. Jemal A,
    2. Bray F,
    3. Center MM,
    4. Ferlay J,
    5. Ward E,
    6. Forman D
    (2011) Global cancer statistics. CA Cancer J Clin 61:69–90.
    OpenUrlCrossRefPubMedWeb of Science
  2. ↵
    1. Bazarbashi S,
    2. Al Eid H,
    3. Minguet J
    (2017) Cancer Incidence in Saudi Arabia:2012 Data from the Saudi Cancer Registry. Asian Pac J Cancer Prev 18:2437–2444.
    OpenUrl
  3. ↵
    1. Kaufman DS,
    2. Shipley WU,
    3. Feldman AS
    (2009) Bladder cancer. Lancet 374:239–249.
    OpenUrlCrossRefPubMedWeb of Science
  4. ↵
    1. Botteman MF,
    2. Pashos CL,
    3. Redaelli A,
    4. Laskin B,
    5. Hauser R
    (2003) The health economics of bladder cancer:a comprehensive review of the published literature. Pharmacoeconomics 21:1315–1330.
    OpenUrlCrossRefPubMedWeb of Science
  5. ↵
    1. Blander G,
    2. Guarente L
    (2004) The Sir2 family of protein deacetylases. Annu Rev Biochem 73:417–435.
    OpenUrlCrossRefPubMedWeb of Science
  6. ↵
    1. Saunders LR,
    2. Verdin E
    (2007) Sirtuins:critical regulators at the crossroads between cancer and aging. Oncogene 26:5489–5504.
    OpenUrlCrossRefPubMedWeb of Science
  7. ↵
    1. Karbasforooshan H,
    2. Roohbakhsh A,
    3. Karimi G
    (2018) SIRT1 and microRNAs:The role in breast, lung and prostate cancers. Exp Cell Res 367:1–6.
    OpenUrl
  8. ↵
    1. Gharabaghi MA
    (2018) Diagnostic investigation of BIRC6 and SIRT1 protein expression level as potential prognostic biomarkers in patients with non-small cell lung cancer. Clin Respir J 12:633–638.
    OpenUrl
  9. ↵
    1. Han F,
    2. Zhang S,
    3. Liang J,
    4. Qiu W
    (2018) Clinicopathological and predictive significance of SIRT1 and peroxisome proliferator-activated receptor gamma in esophageal squamous cell carcinoma:The correlation with EGFR and Survivin. Pathol Res Pract 214:686–690.
    OpenUrl
    1. Ruan L,
    2. Wang L,
    3. Wang X,
    4. He M,
    5. Yao X
    (2017) SIRT1 contributes to neuroendocrine differentiation of prostate cancer. Oncotarget 9:2002–2016.
    OpenUrl
  11. ↵
    1. Jiang H,
    2. Zhang X,
    3. Tao Y,
    4. Shan L,
    5. Jiang Q,
    6. Yu Y,
    7. et al.
    (2016) Prognostic and clinicopathologic significance of SIRT1 expression in hepatocellular carcinoma. Oncotarget 8:52357–52365.
    OpenUrl
    1. Hong WG,
    2. Pyo JS
    (2018) The clinicopathological significance of SIRT1 expression in colon cancer:An immunohistochemical study and meta-analysis. Pathol Res Pract 214:1550–1555.
    OpenUrl
    1. Qiu G,
    2. Li X,
    3. Wei C,
    4. Che X,
    5. He S,
    6. Lu J,
    7. et al.
    (2016) The Prognostic Role of SIRT1-Autophagy Axis in Gastric Cancer. Dis Markers 2016:6869415.
    OpenUrl
  14. ↵
    1. Mvunta DH,
    2. Miyamoto T,
    3. Asaka R,
    4. Yamada Y,
    5. Ando H,
    6. Higuchi S,
    7. et al.
    (2017) Overexpression of SIRT1 is Associated With Poor Outcomes in Patients With Ovarian Carcinoma. Appl Immunohistochem Mol Morphol 25:415–421.
    OpenUrl
    1. Sung JY,
    2. Kim R,
    3. Kim JE,
    4. Lee J
    (2010) Balance between SIRT1 and DBC1 expression is lost in breast cancer. Cancer Sci 101:1738–1744.
    OpenUrlCrossRefPubMed
    1. Zhao G,
    2. Cui J,
    3. Zhang JG,
    4. Qin Q,
    5. Chen Q,
    6. Yin T,
    7. et al.
    (2011) SIRT1 RNAi knockdown induces apoptosis and senescence, inhibits invasion and enhances chemosensitivity in pancreatic cancer cells. Gene Ther 18:920–928.
    OpenUrlCrossRefPubMedWeb of Science
  17. ↵
    1. Asaka R,
    2. Miyamoto T,
    3. Yamada Y,
    4. Ando H,
    5. Mvunta DH,
    6. Kobara H,
    7. et al.
    (2015) Sirtuin 1 promotes the growth and cisplatin resistance of endometrial carcinoma cells:a novel therapeutic target. Lab Invest 95:1363–1373.
    OpenUrl
  18. ↵
    1. Compton CC,
    2. Byrd DR,
    3. Garcia-Aguilar J,
    4. Kurtzman SH,
    5. Olawaiye A,
    6. Washington MK
    (2012) AJCC Cancer Staging Atlas (Springer, New York (NY)), 2 ed Edition.
  19. ↵
    1. Moch H,
    2. Cubilla AL,
    3. Humphrey PA,
    4. Reuter VE,
    5. Ulbright TM
    (2016) The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part A:Renal, Penile, and Testicular Tumours. Eur Urol 70:93–105.
    OpenUrlCrossRefPubMed
  20. ↵
    1. Al-Maghrabi J,
    2. Emam E,
    3. Gomaa W,
    4. Saggaf M,
    5. Buhmeida A,
    6. Al-Qahtani M,
    7. et al.
    (2015) c-MET immunostaining in colorectal carcinoma is associated with local disease recurrence. BMC Cancer 15:676.
    OpenUrl
  21. ↵
    1. Bradley EW,
    2. Carpio LR,
    3. van Wijnen AJ,
    4. McGee-Lawrence ME,
    5. Westendorf JJ
    (2015) Histone Deacetylases in Bone Development and Skeletal Disorders. Physiol Rev 95:1359–1381.
    OpenUrlCrossRefPubMed
  22. ↵
    1. Fadri-Moskwik M,
    2. Weiderhold KN,
    3. Deeraksa A,
    4. Chuang C,
    5. Pan J,
    6. Lin SH,
    7. et al.
    (2012) Aurora B is regulated by acetylation/deacetylation during mitosis in prostate cancer cells. FASEB J 26:4057–4067.
    OpenUrlCrossRefPubMed
  23. ↵
    1. Gong J,
    2. Wang H,
    3. Lou W,
    4. Wang G,
    5. Tao H,
    6. Wen H,
    7. et al.
    (2018) Associations of sirtuins with clinicopathological parameters and prognosis in non-small cell lung cancer. Cancer Manag Res 10:3341–3356.
    OpenUrlCrossRef
    1. Jiang B,
    2. Chen JH,
    3. Yuan WZ,
    4. Ji JT,
    5. Liu ZY,
    6. Wu L,
    7. et al.
    (2016) Prognostic and clinical value of Sirt1 expression in gastric cancer:A systematic meta-analysis. J Huazhong Univ Sci Technolog Med Sci 36:278–284.
    OpenUrl
  25. ↵
    1. Cao YW,
    2. Li YC,
    3. Wan GX,
    4. Du XM,
    5. Li F
    (2015) Clinicopathological and prognostic role of SIRT1 in breast cancer patients:a meta-analysis. Int J Clin Exp Med 8:616–624.
    OpenUrl
  26. ↵
    1. Kang YY,
    2. Sun FL,
    3. Zhang Y,
    4. Wang Z
    (2018) SIRT1 acts as a potential tumor suppressor in oral squamous cell carcinoma. J Chin Med Assoc 81:416–422.
    OpenUrl
  27. ↵
    1. Jeh SU,
    2. Park JJ,
    3. Lee JS,
    4. Kim DC,
    5. Do J,
    6. Lee SW,
    7. et al.
    (2017) Differential expression of the sirtuin family in renal cell carcinoma:Aspects of carcinogenesis and prognostic significance. Urol Oncol 35:675.e9–675.e15.
    OpenUrl
  28. ↵
    1. Cao R,
    2. Wang G,
    3. Qian K,
    4. Chen L,
    5. Ju L,
    6. Qian G,
    7. et al.
    (2018) TM4SF1 regulates apoptosis, cell cycle and ROS metabolism via the PPARγ-SIRT1 feedback loop in human bladder cancer cells. Cancer Lett 414:278–293.
    OpenUrlCrossRef
    1. Cao R,
    2. Wang G,
    3. Qian K,
    4. Chen L,
    5. Qian G,
    6. Xie C,
    7. et al.
    (Jul 20, 2017) Silencing of HJURP induces dysregulation of cell cycle and ROS metabolism in bladder cancer cells via PPARγ-SIRT1 feedback loop. J Cancer 8:2282–2295.
    OpenUrlCrossRefPubMed
  30. ↵
    1. Hu Q,
    2. Wang G,
    3. Peng J,
    4. Qian G,
    5. Jiang W,
    6. Xie C,
    7. et al.
    (2017) Knockdown of SIRT1 Suppresses Bladder Cancer Cell Proliferation and Migration and Induces Cell Cycle Arrest and Antioxidant Response through FOXO3a-Mediated Pathways. Biomed Res Int 2017:3781904.
    OpenUrl
  31. ↵
    1. Lin MH,
    2. Lee YH,
    3. Cheng HL,
    4. Chen HY,
    5. Jhuang FH,
    6. Chueh PJ
    (2016) Capsaicin Inhibits Multiple Bladder Cancer Cell Phenotypes by Inhibiting Tumor-Associated NADH Oxidase (tNOX) and Sirtuin1 (SIRT1). Molecules 21.
  32. ↵
    1. Cao R,
    2. Meng Z,
    3. Liu T,
    4. Wang G,
    5. Qian G,
    6. Cao T,
    7. et al.
    (2016) Decreased TRPM7 inhibits activities and induces apoptosis of bladder cancer cells via ERK1/2 pathway. Oncotarget 7:72941–72960.
    OpenUrl
  33. ↵
    (2016) Correction:Mitochondrial Sirtuins in Cancer:Emerging Roles and Therapeutic Potential. Cancer Res 76:3655.
    OpenUrlFREE Full Text
  34. ↵
    1. van Doeveren T,
    2. van Leeuwen PJ,
    3. Aben KKH,
    4. van der Aa M,
    5. Barendrecht M,
    6. Boevé ER,
    7. et al.
    (2018) Reduce bladder cancer recurrence in patients treated for upper urinary tract urothelial carcinoma:The REBACARE-trial. Contemp Clin Trials Commun 9:121–129.
    OpenUrl
  35. ↵
    1. Nedjadi T,
    2. Salem N,
    3. Khayyat D,
    4. Al-Sayyad A,
    5. Al-Ammari A,
    6. Al-Maghrabi J
    (2018) Sonic Hedgehog Expression is Associated with Lymph Node Invasion in Urothelial Bladder Cancer. Pathol Oncol Res.
  36. ↵
    1. Wang C,
    2. Yang W,
    3. Dong F,
    4. Guo Y,
    5. Tan J,
    6. Ruan S,
    7. et al.
    (2017) The prognostic role of Sirt1 expression in solid malignancies:a meta-analysis. Oncotarget 8:66343–66351.
    OpenUrl
  37. ↵
    1. Song NY,
    2. Surh YJ
    (2012) Janus-faced role of SIRT1 in tumorigenesis. Ann N Y Acad Sci 1271:10–19.
    OpenUrlCrossRefPubMedWeb of Science
  38. ↵
    1. Hishida T,
    2. Nozaki Y,
    3. Nakachi Y,
    4. Mizuno Y,
    5. Iseki H,
    6. Katano M,
    7. et al.
    (2012) Sirt1, p53, and p38(MAPK) are crucial regulators of detrimental phenotypes of embryonic stem cells with Max expression ablation. Stem Cells 30:1634–1644.
    OpenUrlPubMed
  39. ↵
    1. Poyet C,
    2. Jentsch B,
    3. Hermanns T,
    4. Schweckendiek D,
    5. Seifert HH,
    6. Schmidtpeter M,
    7. et al.
    (2014) Expression of histone deacetylases 1, 2 and 3 in urothelial bladder cancer. BMC Clin Pathol 14:10.
    OpenUrlCrossRefPubMed
  40. ↵
    1. Junqueira-Neto S,
    2. Vieira FQ,
    3. Montezuma D,
    4. Costa NR,
    5. Antunes L,
    6. Baptista T,
    7. et al.
    (2015) Phenotypic impact of deregulated expression of class I histone deacetylases in urothelial cell carcinoma of the bladder. Mol Carcinog 54:523–531.
    OpenUrl
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools
Bookmark this article

Jump to section